SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is trending as the community aggressively promotes the meme coin through coordinated buying campaigns and social media outreach to drive rapid price appreciation. Participants are actively debating whether to hold through volatility, fueled by speculation that the token is poised for significant gains compared to other trending small-cap crypto assets.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is experiencing significant market interest driven by positive clinical data for its lead oncology asset, TERN-701, which has fueled speculation regarding a potential buyout or strategic partnership. While the stock has seen a substantial rally, community discussion remains polarized, with some investors celebrating the promising efficacy and best-in-disease potential, while others express caution over the company's valuation, cash burn, and the typical volatility associated with early-stage biotech assets.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as traders speculate on a potential parabolic run, drawing significant attention due to its volatile chart patterns and rapid gains. While community members debate whether this is a legitimate long-term play or a classic pump-and-dump scheme, many are actively monitoring its price action for signs of an impending breakout.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is drawing intense investor focus as the market closely monitors the company's transition from mobile architecture to a central role in AI data center CPUs, with the upcoming earnings report acting as a critical catalyst. While community sentiment is divided between skepticism over its premium valuation and optimism regarding its long-term potential in high-margin sectors like robotics and AGI, traders are actively positioning for significant volatility around the announcement.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently experiencing heightened volatility and intense community debate following significant insider stock sales by the CEO and a challenging earnings report. While bearish sentiment focuses on long-term debt and potential management misalignment, bullish investors are betting on a structural turnaround, citing strong forward HRC steel demand, potential POSCO partnership catalysts, and the company's vertically integrated supply chain as indicators for a major valuation re-rating.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as the community closely monitors NASA's strategic shift toward a phased lunar base and the anticipated LTV contract award. Investors are actively debating the long-term growth implications of this infrastructure pivot while navigating significant stock volatility.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is attracting significant market attention as it seeks strategic oncology acquisitions to bolster its pipeline and mitigate the long-term impact of its primary blockbuster drug's patent expiration. The company is actively positioning itself for future growth through potential M&A activity, with the community closely tracking the broader pharmaceutical landscape and speculating on which biotech assets Merck may prioritize next.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following multiple analyst price target increases and robust clinical data from its Investor Day, highlighting strong Phase 2 results in axial spondyloarthritis and promising long-term Phase 3 data in hidradenitis suppurativa. The community is vigorously discussing the stock's significant undervaluation and alleged market manipulation, despite the positive readouts and progress towards regulatory submission.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors debate whether the asset represents a long-term infrastructure play for decentralized AI or a speculative bubble, with sentiment currently driven by a mix of excitement over its upcoming halving and concern regarding its recent price volatility. Community discourse remains polarized, as supporters frequently compare its scarcity model to Bitcoin and point to rapid subnet growth, while skeptics warn that the token is currently overextended and lacks sufficient real-world product adoption to justify current valuations.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors capitalize on a significant disruption in the global LNG market caused by infrastructure damage in Qatar, which analysts expect will drive a long-term supply shortage. The community is actively debating the stock's potential for a short squeeze and long-term valuation growth, with many highlighting the company's favorable positioning compared to international peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LeMaitre Vascular, Inc. $LMAT Shares Acquired by Congress Asset Management Co.

Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The...

LeMaitre Vascular (NASDAQ:LMAT) Stock Passes Above 200-Day Moving Average - What's Next?

LeMaitre Vascular (NASDAQ:LMAT) Share Price Passes Above 200-Day Moving Average - Here's What Happened...

Kennedy Capital Management LLC Has $18.89 Million Holdings in LeMaitre Vascular, Inc. $LMAT

Kennedy Capital Management LLC raised its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 31.6% in the third quarter, according to its most recent 13F filing with the...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces Quarterly Dividend of $0.25

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Thursday, February 19th. Stockholders of record on Thursday, March 12th will be given a dividend of 0.25 per share by the...

First Trust Advisors LP Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT

First Trust Advisors LP boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 35.4% during the 3rd quarter, according to its most recent 13F filing with the Securities...

LeMaitre Vascular, Inc. $LMAT Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 18.6% during the third quarter, according to the company in its most recent Form 13F...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of "Hold" from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has been assigned a consensus rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. Four...

LeMaitre Vascular (NASDAQ:LMAT) Insider Sells $115,142.76 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) insider Trent Kamke sold 1,044 shares of the company's stock in a transaction dated Friday, February 27th. The shares were sold at an average...

LeMaitre Vascular (NASDAQ:LMAT) Director Sells $903,955.20 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director David Roberts sold 8,464 shares of the business's stock in a transaction that occurred on Friday, February 27th. The stock was sold at...

LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $16,014,000.00 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) CEO George Lemaitre sold 150,000 shares of the company's stock in a transaction on Thursday, February 26th. The stock was sold at an average...

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

LMAT
Lemaitre Vascular Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LMAT News

LMATLemaitre Vascular Inc